Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence

Alaiyan, Bilal; Ilyayev, Nadia; Stojadinovic, Alexander; Izadjoo, Mina; Roistacher, Marina; Pavlov, V. N.; Tzivin, Victoria; Halle, David; Pan, Honguang; Trink, Barry; Gure, Ali Osmay; Nissan, Aviram

doi:10.1186/1471-2407-13-196

Cited by 131 publications

(98 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CCAT1 is markedly overexpressed in CRC 84 and is also upregulated in precancerous tissues, including benign inflammatory colonic tissues and adenomatous polyps. 85 CCAT1 can be detected in CRC tissue and in the blood and stool samples of CRC patients. 86 Thus a CCAT1-based blood/stool assay may be explored for the screening and early detection of CRC.…”

Section: Tumor Diagnosismentioning

confidence: 99%

Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application

Pan

2014

Modern Pathology

102

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a class of newly identified non-coding RNA molecules that are emerging as key regulators of tumor initiation and development. Colorectal cancer (CRC) remains a major health problem worldwide, and there remains a need to further refine the current screening approaches as well as provide tailored diagnostic and therapeutic approaches. Multiple dysregulated lncRNAs participate in tumorigenesis through a variety of molecular mechanisms, and various regulatory factors frequently contribute to the aberrant expression of lncRNAs in CRC, thereby allowing malignant transformation. Additionally, the association of dysregulated lncRNAs with specific developmental stages and clinical outcomes indicates their potential as strong diagnostic and prognostic predictors as well as therapeutic targets. Here we provide a brief overview of the known functions of CRC-associated lncRNAs, describe some potential molecular mechanisms that underlie changes in lncRNA expression in CRC, and attempt to uncover their clinical and therapeutic potential. Keywords: colorectal cancer; diagnosis; dysregulation; long non-coding RNA; prognosis High-throughput genome-scale studies have demonstrated that more than 93% of the DNA sequences in the human genome are actively transcribed. 1 However, only approximately 5-10% of the sequences are stably transcribed into mRNA or non-coding RNA (ncRNA). Genome tiling arrays have revealed that the amount of non-coding sequence is at least four times larger than the amount of coding sequence, which indicates that only 1% of the human genome is composed of protein-coding genes and the remaining 4-9% is transcribed into ncRNAs. 2 Therefore, ncRNAs constitute a very large proportion of the total RNA molecules.The function and clinical significance of short regulatory ncRNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), were elucidated first, 3 and the regulatory roles of miRNAs have been broadly recognized in almost all physiological and pathological processes in the body, including carcinogenesis. 4 For example, we previously reported that MIR95 promotes cell proliferation and targets sorting nexin 1 in human colorectal carcinoma; 5 moreover, in colorectal cancer (CRC) patients, the plasma levels of MIR29a and MIR92a are significantly upregulated and the plasma levels of MIR601 and MIR760 are significantly downregulated; thus the levels of these miRNAs have good diagnostic value for CRC screening. 6,7 According to their transcript size, ncRNAs are grouped into two major classes: (i) small ncRNAs with transcripts o200 nucleotides (nt; eg, aforementioned siRNAs and miRNAs, Piwi-interacting RNAs, and some retrotransposon-derived RNAs) and (ii) long non-coding RNAs (lncRNAs), this class includes five broad categories: sense, antisense, bidirectional, intronic, and intergenic, based on the proximity between neighboring transcripts. 8 For a time, lncRNAs was commonly defined as a proteincoding transcripts that is 4200 nt. 9 However, this definition is arbitrary and ...

show abstract

Section: Tumor Diagnosismentioning

confidence: 99%

Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application

Pan

2014

Modern Pathology

102

View full text Add to dashboard Cite

show abstract

“…3,4 Colon cancer-associated transcript 1 (CCAT1), a ~2-kb lncRNA located at chromosome 8q24.21, is first found to be upregulated in colon cancer. 5 Recently, some reports have found that CCAT1 is involved in tumor progression and tumorigenesis in various types of cancers including colon cancer, 6 gastric cancer, 7 and colorectal cancer. 8 The competitive endogenous RNA (ceRNA) mechanism for CCAT1 and microRNAs involving in tumor progression has been reported in some studies, for example, Zhou et al 9 reported the lncRNA CCAT1/miR-490 axis regulated gastric cancer cell migration by targeting hnRNPA1.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA colon cancer–associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression

et al. 2017

View full text Add to dashboard Cite

Hepatocellular carcinoma is an aggressive neoplasm and is one of the most common human cancers. Recently, long non-coding RNAs have been demonstrated to participate in pathogenesis of many diseases including the progression in several cancers. In this study, we found that the long non-coding RNA colon cancer-associated transcript 1 was upregulated in hepatocellular carcinoma tissues (p < 0.05), and high colon cancer-associated transcript 1 expression level was positively associated with tumor volume (p < 0.05) and American Joint Committee on Cancer stage (p < 0.05) in hepatocellular carcinoma patients. Luciferase reporter assays and RNA-pulldown assays showed that colon cancerassociated transcript 1 is a target of miR-490-3p. Real-time quantitative polymerase chain reaction and Western blot analysis indicated that colon cancer-associated transcript 1 regulated cyclin-dependent kinase 1 expression as a competing endogenous RNA by sponging miR-490-3p in hepatocellular carcinoma cells. Furthermore, colon cancer-associated transcript 1 silencing decreased hepatocellular carcinoma cells proliferation and invasion and overexpression promoted cell proliferation and invasion in vitro. These data demonstrated that the colon cancer-associated transcript 1/miR-490-3p/cyclin-dependent kinase 1 regulatory pathway promotes the progression of hepatocellular carcinoma. Inhibition of colon cancer-associated transcript 1 expression may be a novel therapeutic strategy for hepatocellular carcinoma.

show abstract

“…Recently, aberrantly expressed lncRNAs have been found related with CRC. As examples, lncRNAs such as CCAT1 [24][25], CCAT2 [26], HOTAIR [27] and MALAT1 [28] are increased in CRC tissues compared to NATs and have been identified as oncogenes. The lncRNAs can regulate the expression of their target genes, activate some signaling pathways, and promote cell proliferation, metastasis, and tumor recurrence [29][30][31][32].…”

Section: Discussionmentioning

confidence: 99%

A potential biomarker for colorectal cancer: long non-coding RNA RP1-13P20.6

Liu¹,

Wang²,

Song³

et al. 2016

neo

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) occupy the majority of the human genome. Their dysregulation is usually related with the procession of diseases, including tumors. Abnormally expressed lncRNAs have been found in colorectal cancer (CRC), but are not fully understood. In the current study, we determined the expression level of a novel lncRNA-RP1-13P20.6 in 99 pairs of CRC tissues compared to their matched normal adjacent tissues, using real time polymerase chain reaction. We further assessed the correlation between their expression levels and their clinicopathological parameters, and determined the potential of RP1-13P20.6 as a biomarker for CRC. The expression of lncRNA-RP1-13P20.6 in CRC tissues and cell lines decreased significantly with an area under the curve (AUC) of 0.755 (p < 0.001). However, there was no significant difference between the expression levels of lncRNA-RP1-13P20.6 and the clinicopathological characteristics. The abnormal expression level and AUC values suggest that lncRNA-RP1-13P20.6 is a potential biomarker for CRC.

show abstract

Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence

Cited by 131 publications

References 38 publications

Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application

Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application

Long non-coding RNA colon cancer–associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression

A potential biomarker for colorectal cancer: long non-coding RNA RP1-13P20.6

Contact Info

Product

Resources

About